MONTANA MOLECULAR LLC — Department of Health and Human Services SBIR Phase II: NIAID
MONTANA MOLECULAR LLC — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $600,000 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $600,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NIAID
- Solicitation
- PA21-259
- NAICS
- —
- Place of performance
- MT
- Period
- 2022-05-13 → 2024-04-30
Description
SUMMARY STATEMENT The SARS-CoV-2 virus depends upon two proteases for replication, 3CLpro and PLpro. If one or both of these proteases can be blocked, COVID-19 infection can be effectively treated. Montana Molecular makes and sells live cell, fluorescent biosensor assays for disease research and drug discovery. In response to the COVID-19 pandemic, Montana Molecular applied its expertise and background in live cell assay development to build fluorescent biosensors for the SARS-CoV-2 main protease, 3CLpro. The prototype sensor described in this proposal demonstrates feasibility. Direct to Phase II support is requested here to speed the development of even brighter, more sensitive assays for the 3CLpro and PLpro proteases. These assays can be used in high throughput screening for compounds that inhibit the protease, and engage with their target in living, human cells. 406-539-7399 366 Gallatin Park Drive Suite A Bozeman, MT 59715